Medicines Co. (MDCO) Sinks to Lows Following Inclisiran ORION -1 Phase 2 Update

November 15, 2016 12:07 PM EST

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Medicines Co. (NASDAQ: MDCO) is trading to the lows of the session following this afternoon's update on the analysis of Day 90 data for 497 patients, as well as analysis of preliminary Day 180 data for 189 patients, enrolled in the ORION -1 Phase 2 study of inclisiran.

Shares of MDCO last traded down 7.8%. Shares of partner Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) are down 5%.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Trader Talk

Add Your Comment